CSIMarket Company Name, Ticker, Customers, else..
 
Finch Therapeutics Group Inc   (FNCH)
Other Ticker:  
 
 
Price: $11.6500 $0.15 1.304%
Day's High: $11.94 Week Perf: -0.34 %
Day's Low: $ 11.55 30 Day Perf: -7.1 %
Volume (M): 3 52 Wk High: $ 14.26
Volume (M$): $ 33 52 Wk Avg: $4.07
Open: $11.55 52 Wk Low: $0.82



 Market Capitalization (Millions $) 19
 Shares Outstanding (Millions) 2
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -100
 Cash Flow (TTM) (Millions $) -57
 Capital Exp. (TTM) (Millions $) 0

Finch Therapeutics Group Inc
Finch Therapeutics Group Inc is a biotechnology company that develops novel microbial therapies to address various diseases and disorders. The company focuses on harnessing the power of the microbiome, which is the collection of microorganisms that live in and on the human body, to develop innovative treatments. Finch Therapeutics aims to leverage the potential of the microbiome to develop therapies for conditions such as recurrent C. difficile infection, inflammatory bowel disease, and autism spectrum disorder. The company utilizes advanced research techniques and cutting-edge technology to identify specific microbial strains and develop therapies that can restore the balance of the microbiome and improve patient outcomes.


   Company Address: 75 State Street Boston 2109 MA
   Company Phone Number: 229-6499   Stock Exchange / Ticker: NASDAQ FNCH


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Finch Therapeutics Group Inc

FNCH Sees Encouraging Progress Amidst Consolidation in Recent Fiscal Quarter

Interpreting Financial Results: A Closer Look at Finch Therapeutics Group Inc
As an avid investor, I am always on the lookout for promising opportunities in the stock market. Finch Therapeutics Group Inc, a biotechnology company specializing in microbiome therapeutics, has recently released their most recent financial results. Let's dive into the numbers and see what they mean for shareholders.
For the most recent fiscal period, Finch Therapeutics Group Inc reported a significant increase in losses, reaching $-1.51 per share compared to $-0.85 per share a year before. This adverse trend is disheartening for the company, as it indicates a worsening financial performance. However, it is important to note that this loss per share has improved when compared to the preceding reporting season, where it stood at $-4.33 per share. Thus, despite the higher losses, there is a degree of progress being made.
Finch Therapeutics Group Inc

Finch Therapeutics Group Inc Faces Uphill Battle with Massive Shortfall, but Revenue stays Resilient


Subtitle: Revenue Remains Unaffected as the Company Faces an Uphill Battle

As the Q2 2023 financial results for Finch Therapeutics Group Inc were released, Wall Street analysts were taken aback by the massive increase in the shortfall per share. The company reported a shortfall of $-4.33 per share, a significant jump compared to $-0.48 per share from the previous year. Furthermore, this surge in shortfall also represents an increase of $-1.33 per share since the previous financial reporting period.
In contrast, the revenue remained stagnant at $0.00 million, showing no change from the same period a year ago. Moreover, the company reported revenue of $0.36 million in the corresponding financial reporting period a year prior and $0.11 million sequentially. This indicates that despite the financial challenges, Finch Therapeutics Group Inc was successful in maintaining its revenue stream at the same level.
Finch Therapeutics Group Inc

Devastating Plunge in Revenue: Finch Therapeutics Group Inc's First Quarter Report Delivers Shocking Blow to Investors

Investors were left disappointed by Finch Therapeutics Group Inc's first quarter of 2023 financial report, which painted a bleak picture of the company's performance. According to the report, revenue fell by a staggering 69.774% to a mere $0.11 million, while the net loss per share spiked to $-1.33 from $-0.56 in the preceding reporting season a year ago.
The news only got worse when we learned that the net loss for the first quarter of 2023 clocked in at $-63.939 million, up from $-24.567 million in the same period last year. The steep decline in revenue, coupled with the higher net loss, is a cause for concern among investors who have put their faith in the firm.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com